ImmuCell Corporation (ICCC)
NASDAQ: ICCC · Real-Time Price · USD
11.13
+0.40 (3.73%)
Jul 16, 2026, 4:00 PM EDT - Market closed
ImmuCell Employees
ImmuCell had 73 employees as of December 31, 2025. The number of employees decreased by 2 or -2.67% compared to the previous year.
Employees
73
Change
-2
Growth
-2.67%
Revenue / Employee
$410,059
Profits / Employee
-$7,471
Market Cap
100.69M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Verrica Pharmaceuticals | 76 |
| PolyPid | 75 |
| Enlivex | 34 |
| Oncolytics Biotech | 29 |
| Spero Therapeutics | 25 |
| Black Diamond Therapeutics | 21 |
| Coya Therapeutics | 8 |
| NeOnc Technologies Holdings | 5 |
ICCC News
- 7 days ago - Immucell reports preliminary Q2 revenue $7.2M - TheFly
- 7 days ago - ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results - GlobeNewsWire
- 4 weeks ago - ImmuCell Slides: Investor presentation - Filings
- 5 weeks ago - ImmuCell Transcript: AGM 2026 - Transcripts
- 2 months ago - ImmuCell Earnings Call Transcript: Q1 2026 - Transcripts
- 2 months ago - ImmuCell Quarterly report: Q1 2026 - Filings
- 2 months ago - ImmuCell Earnings release: Q1 2026 - Filings
- 2 months ago - ImmuCell Slides: Q1 2026 - Filings